Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[TPS in prostate cancer]

F I Rodríguez-Rubio1, I Monreal, J E Robles

  • 1Departamento de Urología, Facultad de Medicina, Universidad de Navarra, Pamplona.

Actas Urologicas Espanolas
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phylogenetic Relationships within the Excavating Hadromerida (Porifera), with a Systematic Revision.

Cladistics : the international journal of the Willi Hennig Society·2021
Same author

Health questionnaire analysis and development of satisfaction questionnaire for patients treated with extracorporeal shock wave lithotripsy (SATISLIT).

Actas urologicas espanolas·2019
Same author

Severe childhood trauma and clinical and neurocognitive features in schizotypal personality disorder.

Acta psychiatrica Scandinavica·2019
Same author

Risk models for patients with localised renal cell carcinoma.

Actas urologicas espanolas·2017
Same author

Predicting the effectiveness of extracorporeal shock wave lithotripsy on urinary tract stones. Risk groups for accurate retreatment.

Actas urologicas espanolas·2017
Same author

Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.

Actas urologicas espanolas·2014
Same journal

Comparative outcomes of Mini-PCNL and suction-assisted flexible ureteroscopy in patients with renal stones ≥2 cm.

Actas urologicas espanolas·2026
Same journal

Morphometric changes in pelvic floor structure following non-invasive rehabilitation and neuromodulation assessed by ultrasound imaging.

Actas urologicas espanolas·2026
Same journal

Improving long-term monitoring in NMIBC: Digital Uromonitor® (dUM) as a complementary tool to cystoscopy for two-year recurrence risk stratification.

Actas urologicas espanolas·2026
Same journal

i-PCNL: a novel ureteral-catheter application for continuous unidirectional high-flow irrigation during Percutaneous Nephrolithotomy. Technique description and preliminary outcomes.

Actas urologicas espanolas·2026
Same journal

Reconstructing the reconstructed: Outcomes of redo-urethroplasty for recurrent urethral strictures.

Actas urologicas espanolas·2026
Same journal

Functional outcomes of pyeloplasty in children with reduced preoperative renal function: A multicenter study.

Actas urologicas espanolas·2026
See all related articles

Tumor proliferation marker (TPS) levels can help identify progressive prostate cancer. Elevated TPS levels significantly differentiate advanced prostate cancer from other groups, aiding in disease monitoring.

Area of Science:

  • Oncology
  • Biomarkers
  • Urology

Background:

  • Prostate cancer progression monitoring is crucial for effective treatment.
  • Tumor proliferation markers offer potential for assessing disease activity.

Purpose of the Study:

  • To evaluate the utility of the tumor proliferation marker TPS in distinguishing progressive prostate cancer.
  • To establish reference limits for TPS and assess its diagnostic performance.

Main Methods:

  • TPS levels were measured in patients with prostate hyperplasia, prostate cancer in remission, and progressive prostate cancer, alongside controls.
  • Statistical analysis was performed to compare TPS levels between groups.
  • Diagnostic accuracy metrics (sensitivity, specificity, PPV) were calculated to assess TPS's ability to detect progression.

Related Experiment Videos

Main Results:

  • An upper normal limit for TPS was established at 129 U/l (95th percentile).
  • Significantly higher TPS levels were observed in the progressive prostate cancer group compared to controls, prostate hyperplasia, and remission groups (p < 0.001).
  • TPS demonstrated a sensitivity of 71%, specificity of 94%, and positive predictive value of 62% for detecting disease progression.

Conclusions:

  • TPS is a valuable biomarker for identifying progressive prostate cancer.
  • The established normal limit and diagnostic performance metrics support TPS's role in clinical decision-making for prostate cancer patients.